Another randomized, controlled clinical trial compared the use of a polypill (aspirin, angiotensin-converting enzyme inhibitor, and statin) to standard care for the secondary prevention of cardiovascular death and complications after myocardial infarction and documented that the polypill had a significantly lower risk of major adverse cardiovascular events [33]. The gene discussed is ACE; the disease is myocardial infarction.